How Global Medtech Trends Are Reshaping South Asia's Healthcare and Economic Landscape

Introduction

The global medical technology (medtech) landscape is undergoing rapid transformation, driven by structural changes in pricing, care delivery, supply chains, clinical pathways, and enabling technologies. According to Clarivate’s Medtech Trends to Watch 2026 report, five key trends are redefining how companies compete and where growth will occur. For South Asia—a region of over 1.9 billion people with rapidly expanding healthcare needs—these trends carry significant implications for economic development, industrial policy, and regional cooperation.

As South Asian economies seek to attract foreign direct investment (FDI) in manufacturing, strengthen local innovation ecosystems, and improve healthcare access, understanding these global forces is essential. This article explores each trend through the lens of South Asia's transformation, offering strategic analysis for business leaders, investors, and policymakers.

1. China's Volume-Based Procurement Expansion: Lessons for South Asia

China's national volume-based procurement (VBP) program has evolved from a cost-containment measure into a powerful market-shaping mechanism. The latest rounds feature more sophisticated anchor-price logic, deeper price compression, and allocation systems favoring domestic manufacturers. This has forced multinational medtech companies to rethink their China strategies—and the ripple effects are felt across emerging markets.

Why it matters for South Asia:

• South Asian countries like India, Bangladesh, and Pakistan are increasingly adopting similar bulk procurement schemes to reduce healthcare costs. India's Ayushman Bharat scheme and state-level procurement initiatives already mirror some VBP elements.
• Domestic medtech manufacturers in South Asia stand to benefit if they can compete on price and quality. However, price caps may squeeze margins and discourage innovation if not designed carefully.
• Multinationals operating in South Asia must prepare for compressed pricing and volume guarantees, shifting from premium branding to cost-effective positioning.

Regional Impact:
The spread of VBP-like policies in South Asia could accelerate local production, aligning with "Make in India" and similar industrial strategies. It may also attract FDI from global firms seeking to manufacture for both domestic and export markets at lower costs. However, without robust quality standards, there is a risk of a race to the bottom. Regional cooperation on procurement frameworks—for instance through SAARC or BIMSTEC—could harmonize standards and create larger, more attractive markets.

2. Outpatient and ASC Settings: A Growing Opportunity for South Asia

The shift of procedures from hospitals to outpatient settings and ambulatory surgical centers (ASCs) is a dominant trend in the U.S. and Europe. CMS’s 2026 expansion of the ASC Covered Procedure List now includes higher-acuity procedures like cardiac ablation. This migration is driven by cost efficiency, patient preference, and technological advances.

Why it matters for South Asia:

• South Asia has a high burden of chronic diseases, and its healthcare infrastructure is often overstretched. Expanding outpatient and day-surgery capabilities can reduce costs, improve access, and alleviate pressure on tertiary hospitals.
• Countries like India are already seeing a boom in specialized day-surgery centers, particularly in orthopedics and ophthalmology. This creates demand for medtech devices designed for outpatient use—smaller, portable, and easier to operate.
• For medtech companies, adapting product designs for ASC settings is crucial. South Asian manufacturers can seize this niche by developing low-cost, high-volume devices tailored to local needs.

Regional Impact:
The growth of outpatient care in South Asia could enhance healthcare efficiency and attract investment in medical device parks and training facilities. It also supports the rise of medical tourism, as cost-conscious international patients seek affordable procedures in the region. Policymakers should incentivize ASC development through regulatory simplification and public-private partnerships.

3. Global Trade and Supply Chain Pressures: South Asia as a Manufacturing Hub

Supply chain resilience has become a strategic imperative for medtech companies worldwide. Tariff exposure, geopolitical tensions, and material cost fluctuations are prompting firms to diversify sourcing and adopt multi-region manufacturing footprints. This trend is particularly relevant for South Asia.

Why it matters for South Asia:

• South Asia—especially India—is emerging as an alternative manufacturing destination to China. The Indian government’s production-linked incentive (PLI) schemes for medical devices are attracting investment from global firms.
• However, challenges remain: infrastructure gaps, regulatory complexity, and skill shortages need to be addressed. Regional integration could help: for example, cross-border supply chains for raw materials and intermediate goods can reduce costs.
• The trend toward regionalization of supply chains plays into South Asia’s strengths in pharmaceuticals and textiles, providing a template for medtech. Companies are re-evaluating nearshoring options within the region.

Regional Impact:
Strengthening South Asia’s medtech manufacturing base could boost exports, create high-skilled jobs, and reduce import dependence. It also enhances regional trade integration—a key goal for BIMSTEC and SAARC. Governments should collaborate on harmonized standards, simplified customs, and joint infrastructure projects along economic corridors.

4. GLP-1 Therapies: Shifting Patient Behavior and Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management and diabetes is altering clinical pathways. While bariatric surgery remains more effective for substantial weight loss, GLP-1s are changing referral patterns and demand for related devices, including continuous glucose monitors (CGMs) and cardiovascular implants.

Why it matters for South Asia:

• South Asia faces a growing obesity and diabetes epidemic. GLP-1 drugs offer a non-surgical option, but their high cost limits access. This creates a dual opportunity for medtech: low-cost biosimilars of GLP-1s and affordable monitoring devices.
• Indian pharmaceutical companies are already developing biosimilar GLP-1s, which could lower prices and expand use. Meanwhile, local medtech firms can produce CGMs and other accessories.
• The shift in care pathways may reduce demand for bariatric surgery in the short term, but long-term, higher awareness of metabolic health could expand the overall market.

Regional Impact:
The GLP-1 trend underscores the importance of integrated approaches to metabolic disease, combining drugs, devices, and digital health. South Asian startups are well-positioned to innovate in low-cost diagnostics and digital therapeutics. Policymakers should encourage cross-sector collaboration between pharma and medtech to create comprehensive care solutions.

5. Enabling Technologies: Platform-Based Competition and South Asia's Digital Future

Enabling technologies—robotics, imaging, navigation, and digital workflow software—are becoming central to medtech competition. Companies are investing in platform architectures that integrate clinical planning, surgical execution, and postoperative care. Open-platform systems are also gaining traction, offering flexibility.

Why it matters for South Asia:

• South Asia has a vibrant digital health ecosystem, with startups in telemedicine, AI diagnostics, and electronic health records. However, adoption of advanced surgical technologies like robotics remains limited due to cost and training gaps.
• The platform-based competition trend means that medtech companies will increasingly bundle hardware, software, and services. This could accelerate technology transfer to South Asia if local partners are involved in co-development or distribution.
• South Asian engineers and software developers can contribute to global innovation in enabling technologies, particularly in AI and cloud computing. Regional tech hubs like Bengaluru and Hyderabad are already hubs for medtech R&D.

Regional Impact:
Building digital infrastructure—such as data centers and high-bandwidth networks—is critical for enabling technologies to scale in South Asia. Collaboration between governments, multinationals, and local firms can create ecosystems for surgical robotics training and maintenance. This also opens avenues for FDI in tech-driven healthcare services.

Strategic Insights

• Business opportunities: Multinational medtech companies can leverage South Asia’s cost advantages and growing markets by establishing regional manufacturing and R&D centers. Local firms should focus on products tailored to VBP-like procurement and outpatient settings.
• Investment implications: Investors should target companies involved in medical device manufacturing, digital health platforms, and biosimilars. Public-private partnerships in infrastructure (e.g., medical device parks) offer stable returns.
• Policy priorities: Governments must streamline regulations, invest in skills training, and promote regional trade agreements to create a seamless medtech ecosystem. Special attention should be paid to ensuring quality standards in procurement.
• Technology adoption: South Asia can leapfrog by embracing digital and enabling technologies, but this requires internet access, electricity reliability, and cybersecurity frameworks.

Future Outlook (3–5 years)

Over the next half-decade, South Asia’s medtech landscape will likely experience:

• Expansion of local manufacturing driven by PLI schemes and global supply chain shifts. India could emerge as a medtech export hub for Asia and Africa.
• Growth of outpatient and ASC sectors, supported by regulatory changes and private investment. This will drive demand for cheaper, user-friendly devices.
• Increased adoption of GLP-1 therapies as biosimilars become available, along with complementary diagnostics and monitoring devices.
• Digital and platform-based solutions will become more prevalent, especially in telemedicine and AI diagnostics, with South Asian startups playing a key role.
• Regional cooperation on health policy and trade may deepen, especially under BIMSTEC, but political obstacles remain. A South Asian medical devices harmonization initiative could unlock significant economies of scale.

Conclusion

Global medtech trends are not isolated phenomena—they are reshaping South Asia’s healthcare and economic trajectory. By proactively adapting to these trends, the region can improve healthcare outcomes, attract investment, and build competitive industries. The key is strategic alignment between business, government, and regional institutions. South Asia’s future as a medtech player depends on its ability to learn from global shifts while leveraging its unique strengths in scale, talent, and entrepreneurial spirit.